Buch, Englisch, 257 Seiten, HC runder Rücken kaschiert, Format (B × H): 160 mm x 241 mm, Gewicht: 1250 g
Buch, Englisch, 257 Seiten, HC runder Rücken kaschiert, Format (B × H): 160 mm x 241 mm, Gewicht: 1250 g
ISBN: 978-0-306-45895-8
Verlag: Springer US
This book is the first to describe ADEPT in detail. Each chapter reviews an aspect of the immunology, enzymology, biochemistry, chemistry, and cancer chemotherapy which have been integrated into the ADEPT concept. An additional chapter describes the related approach of gene-directed enzyme prodrug therapy (GDEPT). This latter approach is still in its infancy but ADEPT has entered the clinic. The initial clinical studies with ADEPT are included and discussed in detail.
Zielgruppe
Research
Autoren/Hrsg.
Fachgebiete
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Bildgebende Verfahren, Nuklearmedizin, Strahlentherapie Nuklearmedizin, PET, Radiotherapie
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Onkologie, Krebsforschung
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizin, Gesundheitswesen Medizintechnik, Biomedizintechnik, Medizinische Werkstoffe
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Innere Medizin
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Immunologie
- Technische Wissenschaften Sonstige Technologien | Angewandte Technik Medizintechnik, Biomedizintechnik
- Naturwissenschaften Biowissenschaften Biochemie (nichtmedizinisch)
Weitere Infos & Material
1 Introduction.- 1. Introduction.- References.- 2 Prodrugs in Cancer Chemotherapy.- 1. Introduction.- 2. Uses of Prodrugs in Cancer Chemotherapy.- 3. Clinical Use of Prodrugs.- References.- 3 Factors Influencing Tumor-Selective Localization of Antibody Conjugates.- 1. Introduction.- 2. Tumor Physiology.- 3. Properties of the Monoclonal Antibody Vector.- 4. Tumor Antigens.- 5. Manipulation of Tumor Antigenic Expression.- 6. Evaluation of Antigenic Targets for ADEPT.- 7.In VitroCell Culture Problems.- 8. Unforeseen Problems of Specificity.- References.- 4 Enzymes and Prodrugs Used for ADEPT.- 1. Introduction.- 2. Enzymes and Prodrugs Used for ADEPT.- 3. Conclusions.- References.- 5 The Design and Synthesis of Prodrugs for Antibody-Directed Enzyme Prodrug Therapy (ADEPT).- 1. Introduction.- 2. Prodrugs Used in ADEPT.- 3. Summary.- References.- 6 Preparation and Purification of Antibody-Enzyme Conjugates for Therapeutic Applications.- 1. Introduction.- 2. Production of Antibody Fragments.- 3. Chemical Coupling of Antibodies to Enzymes.- 4. Alternatives to Chemical Coupling.- 5. Purification of Conjugates.- 6. Postpurification Modifications.- 7. Future Developments.- References.- 7 Phage Technology for Producing Antibody-Enzyme Fusion Proteins.- 1. Introduction.- 2. Antibody-Targeted Cancer Therapy.- 3. Potential of Engineered Antibodies for Therapy.- 4. Single-chain Fv Antibodies.- 5. The Phage System.- 6. Target Antigens.- 7. Engineered Antibody-Enzyme Fusion Proteins in ADEPT.- 8. Practical Considerations.- 9. Conclusions.- References.- 8 Early Clinical Studies with ADEPT.- 1. Introduction.- 2. Initial Clinical Studies.- 3. Second Clinical Study.- 4. Conclusions.- References.- 9 Gene-Directed Enzyme Prodrug Therapy (GDEPT) of Cancer.- 1. Introduction.- 2. Why GDEPT?.- 3.Enzymes and Prodrugs Used for GDEPT.- 4. Conclusions.- References.- Enzymes and Prodrugs Proposed for Cancer Therapy.- References.